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Abstract
Background: Multiple myeloma is a plasma cell tumour with approximately 5500 new cases in the UK each year.
Ixazomib is a next generation inhibitor of the 20S proteasome and is thought to be an effective treatment for those
who have relapsed from bortezomib. The combination of cyclophosphamide and dexamethasone (CD) is a
recognised treatment option for patients with relapsed refractory multiple myeloma (RRMM) who have relapsed
after treatment with bortezomib and lenalidomide, whilst also often being combined with newer proteasome
inhibitors. The most apparent combination for ixazomib is therefore with CD.
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Methods: MUK eight is a randomised, controlled, open, parallel group, multi-centre phase II trial that will recruit
patients with RRMM who have relapsed after treatment with thalidomide, lenalidomide, and a proteasome inhibitor.
The primary objective of the trial is to evaluate whether ixazomib in combination with cyclophosphamide and
dexamethasone (ICD) has improved clinical activity compared to CD in terms of progression-free survival (PFS).
Secondary objectives include comparing toxicity profiles and the activity and cost-effectiveness of both treatments.
Since opening, the trial has been amended to allow all participants who experience disease progression (as per the
IMWG criteria) on the CD arm to subsequently switch to receive ICD treatment, once progression has been
confirmed with two clinical members of the Trial Management Group (TMG). This ‘switch’ phase of the study is
exploratory and will assess second progression-free survival measured from randomisation to second disease
progression (PFS2) and progression-free survival from the point of switching to second disease progression (PFS
Switch) in participants who switch from CD to ICD treatment.
Discussion: Development of ixazomib offers the opportunity to further investigate the value of proteasome
inhibition through oral administration in the treatment of RRMM. Previous studies investigating the safety and
efficacy of ICD in patients with RRMM demonstrate a toxicity profile consistent with ixazomib in combination with
lenalidomide and dexamethasone, whilst the combination showed possible activity in RRMM patients. Further
investigation of the anti-tumour effect of this drug in RRMM patients is therefore warranted, especially since no
trials comparing CD with ICD have been completed at present.
Trial registration: ISRCTN number: ISRCTN58227268. Registered on 26 August 2015.
Background
Multiple myeloma (MM) is a malignancy of plasma cells,
characterised by proliferation of these cells in the bone
marrow and, usually, abnormal secretion of monoclonal
immunoglobulins. In 2015, there were 5540 new cases of
MM in the UK, an age-standardised incidence of 9.3 per
100,000 population in patients with a new cancer diagno-
sis, and in 2014, there were 2928 deaths from the disease
[1]. Survival rates for MM have improved significantly in
recent decades, with 77% of patients in England and
Wales currently surviving for at least 1 year following
diagnosis, compared to 37% 40 years ago. Ten-year sur-
vival rates have increased from 6 to 33% in the same time
period [1]. Despite these improvements, which can be at-
tributed to advances in both diagnostics and treatment,
MM is incurable and the majority of patients will at some
point require further therapy for relapsed disease.
Treatment options for relapsed patients include both
conventional cytotoxic agents, newer immunomodulatory
agents and proteasome inhibitors, and autologous stem
cell transplantation (ASCT). As with treatment for pri-
mary disease, a combination of treatments is commonly
employed. However, many patients are either refractory to
treatment using existing approved regimens, or will re-
lapse after an initial response. Investigation of further
treatment options for these patients is therefore required.
Ixazomib is a next generation, small molecule inhibitor
of the 20S proteasome that is under development for the
treatment of non-haematological malignancies, lymph-
oma, MM, and other plasma cell dyscrasias. Inhibition
of the 20S proteasome has previously been validated as a
therapeutic target for the treatment of malignancies
using bortezomib [2]; however, some patients do not re-
spond to bortezomib or develop resistance to this drug.
Ixazomib is structurally and pharmacologically distinct
from bortezomib and is orally bioavailable. Furthermore,
it has already been shown to be well-tolerated, with a
favourable toxicity profile and promising efficacy [3–6].
The Myeloma UK (MUK) study, MUK eight, has been de-
veloped to further investigate the potential of ixazomib for
treatment of relapsed/refractory multiple myeloma (RRMM)
(Fig. 1). For patients with RRMM who have relapsed after
treatment with thalidomide, lenalidomide and a proteasome
inhibitor, the combination of cyclophosphamide and dexa-
methasone (CD) is a recognised treatment option alternative
to a novel therapy. CD is also already regularly used, to good
effect, in combination with newer agents including bortezo-
mib. Therefore in the RRMM setting, the most apparent
combination for ixazomib is with CD.
The study has been developed through the MUK Early
Phase Clinical Trials Network (CTN), an innovative col-
laboration which brings together clinical specialists and
researchers, the pharmaceutical industry and NHS regu-
latory bodies to conduct a prioritised and strategic port-
folio of myeloma clinical trials [7].
Current protocol: V3.0, 23/05/2017.
Methods
Study aim
The MUK eight study will evaluate the clinical effectiveness
of ixazomib in combination with cyclophosphamide and
dexamethasone (ICD), as compared to the combination of
cyclophosphamide and dexamethasone alone (CD), in
terms of progression-free survival (PFS): the time from
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randomisation to first disease progression. MUK eight will
recruit patients with RRMM who have relapsed after treat-
ment with thalidomide, lenalidomide and a proteasome
inhibitor.
Study design
MUK eight is designed as a randomised, controlled,
open, parallel group, multi-centre phase II trial. A max-
imum of 250 participants will be recruited and rando-
mised on a 1:1 basis to receive either ICD or CD.
Since opening, in order to increase appeal of the con-
trol arm, the trial has been amended to allow all partici-
pants who experience disease progression (as per the
IMWG criteria) on the CD arm to subsequently switch
to receive ICD treatment, once progression has been
confirmed by two clinical members of the Trial Manage-
ment Group (TMG).
This phase will assess second progression-free survival
measured from randomisation to second disease pro-
gression (PFS2) and progression-free survival from the
Fig. 1 Trial flow diagram
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point of switching to second disease progression (PFS
Switch), as detailed in Fig. 2, in participants who switch
from CD to ICD treatment. Participants who progress
on the ICD arm will be followed up but treated off-trial
as per standard practice.
Primary objective
To evaluate whether ICD has improved clinical activity
compared to CD in terms of progression-free survival
(PFS), in patients with RRMM who have relapsed after
treatment with thalidomide, lenalidomide and a prote-
asome inhibitor.
Secondary objectives
 To further evaluate the clinical activity of ICD with
regard to additional secondary endpoints, detailed in
Table 3
 To determine the safety and toxicity profile of ICD
compared to CD
 To estimate the cost-effectiveness of ICD compared
to CD
 To determine quality of life with ICD compared to
CD
 To assess the impact of baseline Charlson index
score on PFS, overall survival and deliverability of
planned treatment
Exploratory objectives
 To identify possible biomarkers of response to ICD
 To estimate second progression-free survival (PFS2)
measured from randomisation to second disease
progression for those that switch to ICD treatment
following CD treatment
 To estimate progression-free survival from the point
of switching to second disease progression (PFS
Switch) for those that switch to ICD treatment fol-
lowing CD treatment
 To evaluate the clinical activity of ICD with regard
to additional exploratory endpoints, detailed in
Table 3
 To determine the safety and toxicity profile of ICD
after progressing on CD treatment
Sample size
Using data from previous studies, median PFS in the CD
arm is expected to be in the region of 4 to 6 months
whilst median overall survival (OS) in the CD arm is ex-
pected to be around 8months [8–13]. It is anticipated
that the addition of ixazomib to CD (ICD), in RRMM
patients who have relapsed after treatment with thalido-
mide, lenalidomide and a proteasome inhibitor, may im-
prove clinical efficacy by at least 50%, in terms of
median PFS. One formal interim efficacy analysis is
planned for when 70% of the PFS events (139 events)
have been observed, to assess for superiority of ICD.
For the final analysis, assuming median PFS of 6
months in the CD arm, a total of 198 PFS events are re-
quired to detect an improvement in median PFS to 9
months with the addition of ixazomib to CD, corre-
sponding to a hazard ratio of 0.67 (80% power, 4.55% 2-
sided significance level in order to maintain 5% signifi-
cance overall when taking into account the interim ana-
lysis). A total of approximately 230 patients (115
patients per arm) will be needed for patient enrolment
to generate a total of 198 PFS events (Fig. 3). This as-
sumes recruitment over a 24-month period, with an add-
itional minimum 12months’ follow-up. Allowing for
dropout of 8%, a total of 250 participants are required.
With 250 patients generating more than a total of 198
PFS events, this will also provide sufficient power (>
80%) to detect an improvement of 50% in median PFS
where the control arm median PFS is anywhere in the
region of 4 to 6 months.
For the interim analysis, the O’Brien and Fleming [14]
approach will be used in order to maintain an overall 5%
2-sided significance level when performing a single in-
terim analysis before final analysis. Superiority at the
Fig. 2 Explanation of PFS endpoints. *After patients randomised to the CD arm reach disease progression, they are given the option to switch to
ICD treatment until they disease progress a second time. Patients randomised to the ICD arm that reach disease progression will be followed-up
but treated off-trial as per standard practice
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interim analysis, in terms of PFS, will therefore be tested
at a 0.0074 1-sided significance level, whilst the final
analysis will be tested at a 0.0455 2-sided significance
level.
At the interim analysis, assuming median PFS of 6
months in the CD arm, there will be approximately
47% power to detect a hazard ratio of 0.67. A low
power has been used as an early release of data will
only take place at this point if an overwhelming treat-
ment effect is seen.
A total of 186 deaths, which are expected from the
sample size of 250, provide over 80% power to detect
an improvement in median overall survival (OS) from
8months with CD to 11.5 months with ICD, corre-
sponding to a hazard ratio of 0.7, at the 2-sided 10%
significance level.
This ‘switch’ phase of the study is exploratory so no
formal sample size calculation has been performed.
Recruitment process
When calculating the sample size, the trial was ex-
pected to take 24 months to complete recruitment, at
a rate of 15 participants per month, and the first trial
participant was randomised on 21 January 2016.
However, due to slower recruitment than anticipated,
it is likely the trial will take longer than this to
complete recruitment. Participants will be recruited
from NHS hospitals throughout the UK which are ap-
proved research sites within the MUK Early Phase
CTN. A full list of study sites can be accessed via the
trial registration, ISRCTN58227268.
Research sites will be required to have obtained
ethical and management approval and undertake a
site initiation meeting with Clinical Trials Research
Unit (CTRU) prior to opening to recruitment. Poten-
tial participants will be approached by authorised
members of staff, usually during standard clinic visits
for management of their disease, who will verbally de-
scribe and discuss the trial and then provide the pa-
tient information sheet.
Participants will be given as long as they need to
consider whether they wish to take part and will be
able to discuss the study with their family, friends
and other healthcare professionals if they wish. Con-
senting participants will be invited to provide in-
formed, written consent and will be formally assessed
for eligibility, according to the inclusion and exclusion
criteria detailed in Table 1.
Fig. 3 SPIRIT figure: schedule of enrolment, interventions, assessments and analysis
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Randomisation
Written informed consent for entry into the trial must
be obtained, with eligibility being confirmed prior to
randomisation. Randomisation will be administered
using an automated 24-h web-based system managed
by the CTRU. A computer-generated minimisation
programme that incorporates a random element will
be used to balance treatment groups for age (< 60 vs.
60–69 vs. ≥ 70), number of prior lines of therapy (≤ 3
vs. > 3) and β2M (< 3.5 mg/L vs. 3.5 mg/L ≤ β2M < 5.5
mg/L vs. ≥ 5.5 mg/L) at randomisation.
Study centre has not been included as a minimisation
factor as the primary endpoint is standardly assessed
across all centres, as seen from previous trials run
Table 1 MUK eight study inclusion and exclusion criteria
Inclusion criteria
●Able to give informed consent and willing to follow study protocol assessments
●Aged 18 years or over
●Participants with confirmed MM based on IMWG criteria, 2009
●Measurable disease with at least one of the following:
○Paraprotein > 5 g/L or 0.5 g/l for IgD subtype
○Serum free light chains > 100mg/L with abnormal ratio for light chain only myeloma
○Bence Jones protein > 200mg/L
●Participants with relapsed or relapsed refractory myeloma and now require further treatment following exposure to thalidomide, lenalidomide
and a proteasome inhibitor regardless of response to these.
●Participants for which CD would be a suitable treatment
●ECOG Performance Status ≤ 2
●Required laboratory values within 14 days prior to start of treatment:
○Platelet count ≥ 50 × 109/L. Platelet count of 30–50 is acceptable if bone marrow aspirate shows tumour replacement of > 50%. Platelet
support is permitted within 14 days prior to randomisation although platelet transfusions to help patients meet eligibility criteria are not allowed
within 72 h prior to the blood sample to confirm protocol eligibility.
○Absolute neutrophil count ≥ 1.0 × 109/L. Growth factor support is not permitted within 14 days prior to randomisation
○Haemoglobin > 90 g/L. Blood support is permitted
○ALT and / or AST ≤ 3 × upper limit of normal
○Creatinine clearance ≥ 30 ml/min (using Cockcroft Gault formula)
○Bilirubin ≤ 1.5 × upper limit of normal
●Female participants should avoid becoming pregnant and male participants should avoid impregnating a female partner. Both non-sterilised and
sterilised females and males of reproductive age should use effective methods of contraception during the entire trial treatment (including treat-
ment breaks) and up to 90 days after the last dose of trial treatment. Females of child bearing potential will require a negative pregnancy test to
be performed.
●Post allograft patients may be included if > 12months from transplant.
Exclusion criteria
●Participants meeting any of the following exclusion criteria are not eligible to register for this trial.
●The following participants will be excluded:
○Those with non-measurable disease
○Those with a solitary bone or solitary extramedullary plasmacytoma
○Plasma cell leukaemia
●Prior malignancy other than those treated with curative surgery.
●Participants with a known or underlying uncontrolled concurrent illness that, in the investigators opinion, would make the administration of the
study drug hazardous or circumstances that could limit compliance with the study, including, but not limited to the following: acute or chronic
graft versus host disease, uncontrolled hypertension, congestive heart failure ≥ NYHA Class III, unstable angina pectoris, myocardial infarction
within past 6 months, uncontrolled cardiac arrhythmia, renal failure, psychiatric or social conditions that may interfere with participant compliance,
or any other condition (including laboratory abnormalities) that in the opinion of the Investigator places the participant at unacceptable risk for
adverse outcome if he/she were to participate in the study.
●Participants who have previously received MLN9708/ixazomib in a trial. Previous experimental agents or approved anti-tumour treatment within
28 days before the date of randomisation.
●A maximum of 160 mg of dexamethasone (in 40mg blocks) may be given between screening and the beginning of initial treatment if medically
required but should be stopped before trial treatment starts. Bisphosphonates for bone disease are also permitted.
●Participants with a history of a refractory nausea, diarrhoea, vomiting, malabsorption, gastrointestinal surgery or other procedures that might, in
the opinion of the Investigator, interfere with the absorption or swallowing of the study drug(s)
●Peripheral neuropathy of ≥ grade 2 (or grade 1 with pain) severity (as per NCI-CTCAEv4.0)
●Gastrointestinal disorders that may interfere with absorption of the study drug
●Active symptomatic fungal, bacterial, and/or viral infection including known active HIV or known viral (A, B or C) hepatitis
●Female participants who are lactating or have a positive pregnancy test at screening
●Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent that would prevent the
participant receiving these as directed in the protocol
●Systemic treatment, within 14 days prior to the first dose of ixazomib, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin),
strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A
inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John’s wort
●Major surgery within 14 days prior to the date of randomisation
●Radiotherapy within 7 days prior to randomisation for palliative pain control or therapeutic radiotherapy within 14 days prior to randomisation
●Myeloma involving the Central Nervous System.
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through CTRU; therefore, clustering within sites will not
likely be an issue. Additionally, the impact of treatment
groups not being balanced within a centre is thought to
be less problematic than treatment group unbalance
across the minimisation factors selected.
Intervention
Patients randomised to ICD will receive the following
regimen: ixazomib (oral) 4 mg on days 1, 8 and 15; cyclo-
phosphamide (oral) 500mg on days 1, 8 and 15; and dexa-
methasone (oral) 40mg on days 1–4 and 12–15.
Patients randomised to CD will receive the following
regimen: cyclophosphamide (oral) 500 mg on days 1, 8
and 15 and dexamethasone (oral) 40 mg on days 1–4
and 12–15.
For older/less fit patients in both cohorts (as deter-
mined by the Principal Investigator), dexamethasone
may be given orally at 20 mg on days 1–4 and 12–15.
In both cohorts, the cycle is repeated every 28 days
with response being assessed at the end of each cycle.
Before commencing, a new cycle of treatment the par-
ticipant must meet the parameters set in the eligibility
criteria (including laboratory results), given in Table 1.
Participants will continue on the trial regimen until dis-
ease progression, death, unacceptable toxicity or with-
drawal of consent, whichever is sooner.
Participants randomised to CD alone may switch to
receive ICD, according to the same schedule above, once
disease progression is confirmed both by two TMG clin-
ical members and two consecutive assessments (as de-
fined by the IMWG response criteria), and eligibility has
been confirmed as detailed in Table 2.
If a participant’s cyclophosphamide and/or dexametha-
sone doses have been reduced during the CD only phase
of the trial, they will remain at the same dose when
moving on to ICD.
Trial assessments
Written informed consent must be obtained prior to the
commencement of trial-specific assessments, and base-
line assessments are to be performed within 14 days
prior to randomisation. The required baseline assess-
ments include a physical examination, ECOG perform-
ance status, medical history, ISS stage and ECG, as well
as haematology, biochemistry and bone marrow sample
tests. Participants must also complete the EQ-5D (5-
level) and EORTC QLQ-C30 quality of life question-
naires prior to randomisation.
Assessments to be carried out within 48 h prior to the
start of each cycle of treatment include a physical exam-
ination, peripheral neuropathy assessment, ECOG per-
formance status, recording of adverse reactions and
concomitant medications, and haematology and bio-
chemistry tests. Participants will also complete the EQ-
5D (5-level), EORTC QLQ-C30 and Resource Use ques-
tionnaires every 3 cycles. Laboratory results must be
available and reviewed by the clinical team before dosing
on day 1 of each cycle of treatment. Full blood counts
will also be performed on days 8, 15 and 22 of cycles 1–
3, and for the first 3 cycles of ICD following CD treat-
ment. Blood samples for central investigations will be
taken in cycle 4. Haematology and biochemistry results
must remain within the parameters outlined in the eligi-
bility criteria to proceed with each cycle of treatment.
End of treatment assessments, at the end of initial ran-
domised treatment (CD or ICD) and at the end of the
switch to ICD treatment, include a physical examination,
peripheral neuropathy assessment, ECOG performance
status, recording of adverse reactions and concomitant
medications, and haematology, biochemistry and bone
marrow tests. Participants will also complete the three
quality of life questionnaires as before.
All participants will be followed up 4-weekly post the
end of treatment until second disease progression.
Follow-up will involve a response assessment and
reporting of adverse reactions and SAEs will occur until
60 days post the last dose of trial treatment. Participants
will be asked to complete the questionnaires at 3-month
intervals until second disease progression. Participants
who switch to ICD after treatment with CD will be
followed up for 60 days post the end of treatment for
toxicity (even if they stop treatment for (second) disease
progression). After first disease progression, all
Table 2 MUK eight inclusion criteria for switching to ICD
treatment
Inclusion criteria for switching to ICD
●Randomised and treated in the CD only arm of the MUK eight trial
●Centrally confirmed disease progression by IMWG criteria. This must
be confirmed by two consecutive assessments, local laboratory
reports and confirmation of this must have been received via email
from CTRU.
●ECOG performance status ≤ 2
●Required laboratory values within 14 days prior to start of ICD
treatment:
○ Platelet count ≥ 50 × 109/L. Platelet count of 30–50 is acceptable
if bone marrow aspirate shows tumour replacement of > 50%.
Platelet transfusions to help patients meet these criteria are not
allowed within 72 h prior to the blood sample to confirm eligibility
to switch to ICD.
○ Absolute neutrophil count ≥ 1.0 × 109/L. Growth factor support is
not permitted within 14 days prior to randomisation
○ Haemoglobin ≥ 90 g/L. Blood support is permitted
○ ALT and / or AST ≤ 3 × upper limit of normal
○ Creatinine clearance ≥ 30 ml/min (using Cockcroft Gault formula)
○ Bilirubin ≤ 1.5 × upper limit of normal
●B2M performed within 14 days prior to the start of ICD treatment
●Female participants should avoid becoming pregnant and male
participants should avoid impregnating a female partner. Both non-
sterilised and sterilised females and males of reproductive age should
use effective methods of contraception during the entire trial treat-
ment (including treatment breaks) and up to 90 days after the last
dose of trial treatment. Females of child bearing potential will require
a negative pregnancy test to be performed.
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participants will be followed up for a minimum of 12
months post-randomisation for survival only, until the
time of final analysis.
Data collection, management and monitoring
Participants will be identified by hospital sites during
haematology clinic visits, and consent forms will be col-
lected and checked to ensure all participants are con-
sented fully. All data collected will be anonymised with a
participant trial ID and sent with date of birth and ini-
tials to ensure accurate identification of participants for
data entry. Data entry will be performed from paper
Case Report Forms (CRFs) completed by each hospital
site by internal staff and stored on the secure trial data-
base accessed only by authorised members of CTRU
staff. EORTC EQ-5D and QLQ-C30 will be used to col-
lect quality of life data, in accordance with the EORTC
instructions provided, therefore deemed valid and
reliable.
Data management processes are fully documented in a
trial work instructions document. Data will be 100% data
checked for all items relating to trial endpoints and
safety, i.e. doses of treatment and adverse reactions, for
data quality. For any participant reaching the end of the
trial on the CD arm and switching to the ICD arm, la-
boratory reports will be collected to verify this.
Adverse reactions will be collected on the CRF and
100% checked and data managed in the hope that this
will ensure the data is accurate. Serious adverse events
and suspected unexpected serious adverse events will be
collected in real time with all being reviewed by the
Chief Investigator within 24 h to guard against harm
coming to the patient. Bleeding events will be closely
monitored for the first 5 patients receiving ixazomib due
to concerns regarding a low platelet count at inclusion.
Statistical methods and analysis
For all statistical analyses, the analysis population (par-
ticipants that are evaluable for the primary endpoints),
as well as the safety population (participants that are
evaluable for the toxicity and safety endpoints), are de-
fined as those who receive at least one dose of any trial
treatment. Toxicity and safety endpoints will be assessed
according to the treatment actually received whilst ef-
fectiveness endpoints will be assessed by treatment the
patient is randomised to. For example, patients on the
ICD arm that do not receive ixazomib will be analysed
together with the ICD patients that have received
ixazomib.
Interim analysis
One formal interim efficacy analysis is planned for when
70% of the PFS events (139 events) have been observed,
to assess for superiority of ICD in terms of PFS, and is
estimated to take place at the same time as completing
recruitment. This interim analysis is detailed in a Data
Monitoring and Ethics Committee (DMEC) Interim
Statistical Analysis Plan, and if, at the time of this in-
terim analysis, ICD is found to be significantly superior
when compared to CD, the DMEC may report to the
Trial Steering Committee (TSC) with a recommendation
of early release of data, rather than a recommendation of
early trial closure. If the timing of this interim analysis
falls before the end of recruitment, the DMEC may re-
port to the TSC with a recommendation of early trial
closure if appropriate.
Primary endpoint analysis
The primary endpoint analysis will compare the ICD
arm to the CD arm in terms of PFS, with a null hypoth-
esis of no difference between ICD and CD, and an alter-
native hypothesis of a difference between ICD and CD
with ICD expected to be superior to CD. PFS curves will
be calculated using the Kaplan-Meier method and the
median PFS estimates and PFS estimates at 6 and 12
months with corresponding 95% confidence intervals
will be presented by treatment group. A log-rank test,
stratifying for the minimisation factors, will be used to
compare PFS between the treatment groups.
The proportional hazards assumption will be assessed
by plotting the hazards over time for each treatment
arm, in addition to using the methods of Lin et al. [15]
to check the adequacy of the Cox regression model. If
the assumptions for Cox’s proportional hazards (Cox
PH) model can be verified, a Cox PH model will be used.
This model will adjust for the minimisation factors and
other important prognostic factors identified by the
TMG, in order to identify factors predictive of PFS be-
tween the treatment arms. Parameter estimates, standard
errors, hazard ratios and 95% CIs, and p values will be
presented for treatment and all other covariates included
in the model.
Secondary endpoint analysis
For secondary endpoint analyses, maximum response is
defined as the proportion of participants achieving each
of the response categories sCR, CR, VGPR, PR, MR, SD
or PD as their maximum response to initial treatment.
Logistic regression adjusting for treatment group and
minimisation factors will be used to predict the propor-
tion of patients achieving at least a PR, and ordered lo-
gistic regression will be used to analyse the proportion
of patients in each maximum response category, where
appropriate (i.e. should the number of events in each
maximum response level be sufficient).
The Kaplan-Meier method and log-rank test will be
used to summarise the difference between treatment
arms in terms of time to maximum response, duration
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of response and overall survival. If the Cox PH assump-
tions are confirmed as valid, a Cox PH model will also
be fitted for these endpoints, in addition to the time to
progression endpoint, provided no competing risk events
have occurred. Residuals and predicted values produced
from any multivariate models will be examined to assess
the assumptions of the model. Competing risk analyses
using cumulative incidence functions will be conducted
for time to progression and time to maximum response
endpoints. For these endpoints respectively, patients that
have died with no previous evidence of disease progres-
sion and patients that have died prior to achieving a
maximum response will be classed as having had a com-
peting risk. Those not evaluable for maximum response
(i.e. those with no response assessments following com-
mencement of treatment) will be summarised as ‘no
maximum response’ and excluded from analyses.
The cost-effectiveness analysis will consist of a deci-
sion model analysis informed by the trial data (patient
reported resource use and the EQ-5D-5L) along with
data from the wider literature and other sources where
necessary. The primary analysis will be conducted from
the healthcare provider perspective and report cost per
quality-adjusted life year (QALY) gain over a lifetime
horizon. Deterministic and stochastic sensitivity analyses
will be performed. The analysis will be outlined in full in
a health economics analysis plan ahead of analysis
commencing.
Quality of life (QoL) will be summarised descriptively
for each post-randomisation time-point using bar charts,
box plots, plots of mean QoL over time and summary
tables. Differences between treatment groups will also be
obtained using a multi-level repeated measures model
accounting for data at all post-baseline time points, as-
suming missing data at random (MAR). Missing data
patterns will be examined, and sensitivity analyses using
different missing data assumptions will be performed
where appropriate, as described below.
A summary of the main comparisons and analysis
methods for each secondary endpoint are given in Table 3.
Sensitivity analyses for PFS and OS will be performed
using imputed dates if there are > 5% of participants
with a completely missing date of death/progression.
Sensitivity analyses will also be conducted if there are >
5% of partially missing dates, using the earliest and latest
possible day of the month. Sensitivity analyses for QoL
Table 3 MUK eight secondary and exploratory endpoint analysis
Secondary (S) and exploratory (E) endpoints Analysis method(s)
S(i) Proportion of patients achieving at least Partial Response [D1] Logistic regression
S(ii) Proportion of patients in each maximum response category [D1] Ordered logistic regression
S(iii) Time to progression [D1] CIF and log-rank test, Cox PH
S(iv) Time to maximum response [D1] Kaplan-Meier and log-rank test, Cox PH, CIF
S(v) Duration of response [D1] Kaplan-Meier and log-rank test, Cox PH
S(vi) Overall survival [D1] Kaplan-Meier and log-rank test, Cox PH
S(viii) Treatment compliance [NFT] Descriptive summaries
S(ix) Safety and toxicity [NFT] Descriptive summaries
S(x) Cost-effectiveness [HE] Cost-utility analysis, cost effectiveness acceptability curves
S(xi) Quality of life [D1] Multi-level repeated measures model
E(i) To identify possible biomarkers of response to ICD [NFT] Descriptive summaries
E(ii) To estimate PFS2 for those that switch to ICD following CD treatment [NFT] Kaplan-Meier and [D2] exploratory analyses: Kaplan-Meier
and log-rank test, Cox PH
E(iii) To estimate PFS Switch for those that switch to ICD following CD treatment [NFT] Kaplan-Meier and [D3] exploratory analyses of the ratio
of PFS from switch against PFS on CD pre-switch
E(iv) Proportion of patients achieving at least Partial Response for
ICD following CD treatment
[NFT] Descriptive summaries
E(v) Proportion of patients in each maximum response category
of ICD following CD treatment
[NFT] Descriptive summaries
E(vi) Time to maximum response for ICD following CD treatment [NFT] Kaplan-Meier
E(vii) Duration of response for ICD following CD treatment [NFT] Kaplan-Meier
E(viii) Treatment compliance for ICD following CD treatment [NFT] Descriptive summaries
E(ix) Safety and toxicity for ICD following CD treatment [NFT] Descriptive summaries
D1 differences between treatment arms (ICD vs CD), D2 differences between treatment arms (ICD vs ICD Switch after progression on CD), D3 differences between
treatments (CD vs ICD Switch after progression on CD), NFT no formal statistical testing, HE health economic analysis, Cox PH Cox’s proportional hazards model,
CIF cumulative incidence function curves for competing risk analysis
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may be carried out using methods such as multiple im-
putation, pattern-mixture multi-level models categoris-
ing participants into strata based on clinical information
which is believed to represent the reasons for missing
data (assuming MAR data conditional upon participants’
clinical data), and pattern mixture models for bivariate
(baseline and 9 week) data fitted using a variety of re-
strictions reflecting the missing data pattern ranging
from complete case missing variable restriction (MAR)
to Brown’s protective restriction (assuming data are
missing not at random (MNAR)).
PFS and OS will also be analysed adjusting for baseline
Charlson Comorbidity Index [16] score (0, 1–2, > 2),
which is calculated by assigning scores to each partici-
pant’s age and any comorbidities they exhibit, then sum-
ming the total of these scores. By including the Charlson
Comorbidity Index scores in the Cox’s proportional haz-
ards model for PFS and OS, this will determine the
prognostic value of baseline Charlson index score on
these outcomes. An interaction between baseline Charl-
son index score and treatment will also be included in
the Cox proportional hazards models to assess the impact
of the baseline score on treatment’s effect on the outcome.
Deliverability of planned treatment according to baseline
Charlson index score will be assessed by summarising the
treatment compliance and toxicity endpoints according to
participants’ baseline score (0, 1–2, > 2).
Exploratory analyses to investigate biomarkers of re-
sponse will also be performed. These analyses will be de-
tailed in full in a separate statistical analysis plan prior
to any analysis undertaken.
Further exploratory analyses, detailed in Table 3, will
be conducted for the switch phase of the trial, where pa-
tients on the CD arm may receive ICD treatment after
confirmed progression on CD. These will include PFS2,
PFS Switch, treatment compliance, and safety and tox-
icity. The definitions of PFS, PFS2 and PFS Switch are
visualised in Fig. 2.
Frequency of analyses
A DMEC (made up of at least two clinicians and one
statistician that are independent of the study team) will
be set up to review data on safety, activity, protocol ad-
herence and recruitment. The DMEC will review safety
data for all participants entered into the trial after 12
participants have been recruited, and 3-monthly there-
after. Interim reports containing safety data, protocol ad-
herence and recruitment will be presented to the DMEC
in strict confidence at, at least, yearly intervals. This
committee, in light of the interim data, and any advice
and evidence they wish to request, will if necessary re-
port to the TSC if there are any concerns regarding the
activity or safety of the trial treatments.
The DMEC may also report to the TSC, with a recom-
mendation of early release of data, should ICD be found
to be significantly superior to CD during the interim
analysis (once 70% of PFS events have been observed).
Final analysis will take place in two stages. Analysis of the
primary endpoint will take place when at least 198 PFS
events have been observed. At this time, all other endpoints
relating to the first ‘phase’ of the study, with the exception
of OS, will be analysed. A decision will be made based on
the overall number of deaths observed as to whether OS
will be analysed at the same time as PFS, or whether add-
itional follow-up is required prior to analysis. Analyses re-
lating to the switch phase of the study will take place after a
minimum of 6months follow-up after the last CD partici-
pant to switch treatments has started ICD treatment.
Discussion
Despite advances in treatment options and improvements
in survival rates over recent years, the overall prognosis
for MM patients remains poor. Most patients will respond
to initial treatment, potentially entering a plateau phase
for a number of years, but relapse is inevitable. Subse-
quent response can be obtained by re-treating with the
same or different regimens; however, some patients will
become refractory to existing standard treatments. Ixazo-
mib offers the opportunity to further investigate the value
of proteasome inhibition in the treatment of RRMM
whilst carrying the benefits of oral administration.
Two phase I studies have already investigated ixazomib
in the RRMM setting [3, 5, 17]. These studies both incor-
porated a dose escalation phase followed by a dose expan-
sion phase and indicated that ixazomib is well tolerated,
with manageable toxicities. Dose limiting toxicities seen in
these studies were skin rash, thrombocytopenia, nausea,
diarrhoea, vomiting and erythema multiforme. Addition-
ally a phase II study has investigated the safety and efficacy
of ICD in patients with RRMM [18]. This study demon-
strated a toxicity profile consistent with that seen in
ixazomib in combination with lenalidomide and dexa-
methasone, whilst the combination appeared to have ac-
tivity in RRMM patients. The promising clinical activity
demonstrated in these studies, with durable responses and
disease control, prove that further investigation of the
anti-tumour effect of this drug in RRMM patients is war-
ranted, especially given that no trials comparing CD with
the combination of ixazomib and CD have been com-
pleted at present. As of today, there has been no evidence
of impact on trial recruitment of ixazomib (Ninlarao) be-
ing available through the Cancer Drugs fund in England
and SMC in Scotland. Ixazomib is not accessible in North-
ern Ireland. We therefore believe that demonstration of
an improvement in PFS and overall survival for patients
treated with ICD compared to CD would act as support-
ing evidence for the use of ixazomib in the UK.
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